Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Research of Metabolomics in Clinical Immunology
share announcement

Research of Metabolomics in Clinical Immunology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 3516

Special Issue Editor

Dr. Anna Artati

E-Mail Website
Guest Editor
Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
Interests: non-targeted metabolomics; immunology; apoptosis; immunotherapy

Special Issue Information

Dear Colleagues,

In the last decades, there has been a huge increase of interest on the applications of metabolomics in health research including in the area of immunology. As endpoint of biological processes in organisms, metabolites reflect a readout of the dynamic processes in relation to genetic variations, gene expressions, protein functions, and external factors like allergens, drug therapies, nutrition, and lifestyles, which can trigger various diseases related to the immune system. This omics technology allows better understanding not only in human physiology and diseases mechanisms, but also in identifying biomarkers and responses to treatments.  

This Special Issue aims to disseminate the latest research on metabolomics in all areas of immunology, from fundamental mechanisms to applied aspects.

We are pleased to invite you to submit research papers or comprehensive reviews on all aspects related to the theme of this Special Issue. Research areas may include (but not limited) to metabolomics studies in following areas:

  • Allergy and asthma
  • Autoimmunity
  • Development and function of cells of the immune system
  • Infection and immunity
  • Immunotherapy
  • Regulation of the immune response
  • Signalling in the immune system
  • Innate immunity
  • Mucosal immunology and the microbiota
  • Antigen processing and presentation
  • Apoptosis and cell death
  • Tumour immunology and immunotherapy
  • Chemokines and chemokine receptors
  • Cytokines and cytokine receptors
  • Vaccine development

We look forward to hearing from you soon!

Dr. Anna Artati
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • personalized medicine
  • immunology
  • allergy and asthma
  • cells of the immune system
  • infection and immunity
  • immunotherapy
  • apoptosis
  • cancer

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

23 pages, 1603 KiB  
Review
Metabolic Profiling in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: Elucidating Pathogenesis, Improving Diagnosis, and Monitoring Disease Activity
by Erika Dorochow, Michaela Köhm, Lisa Hahnefeld and Robert Gurke
J. Pers. Med. 2022, 12(6), 924; https://doi.org/10.3390/jpm12060924 - 2 Jun 2022
Cited by 9 | Viewed by 3135
Abstract
Immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (Ps), represent autoinflammatory and autoimmune disorders, as well as conditions that have an overlap of both categories. Understanding the underlying pathogeneses, making diagnoses, and choosing individualized treatments remain challenging [...] Read more.
Immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (Ps), represent autoinflammatory and autoimmune disorders, as well as conditions that have an overlap of both categories. Understanding the underlying pathogeneses, making diagnoses, and choosing individualized treatments remain challenging due to heterogeneous disease phenotypes and the lack of reliable biomarkers that drive the treatment choice. In this review, we provide an overview of the low-molecular-weight metabolites that might be employed as biomarkers for various applications, e.g., early diagnosis, disease activity monitoring, and treatment-response prediction, in RA, PsA, and Ps. The literature was evaluated, and putative biomarkers in different matrices were identified, categorized, and summarized. While some of these candidate biomarkers appeared to be disease-specific, others were shared across multiple IMIDs, indicating common underlying disease mechanisms. However, there is still a long way to go for their application in a routine clinical setting. We propose that studies integrating omics analyses of large patient cohorts from different IMIDs should be performed to further elucidate their pathomechanisms and treatment options. This could lead to the identification and validation of biomarkers that might be applied in the context of precision medicine to improve the clinical outcomes of these IMID patients. Full article
(This article belongs to the Special Issue Research of Metabolomics in Clinical Immunology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop